Navigation Links
Intestinal bacteria associated with non-alcoholic fatty liver disease
Date:5/28/2009

Intestinal permeability and an overgrowth of bacteria in the small intestine are both associated with nonalcoholic fatty liver disease (NAFLD). These findings are revealed in a new study in the June issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD). The article is also available online at Wiley Interscience (www.interscience.wiley.com).

Previous studies have suggested that bacteria from the intestine might play a role in NAFLD, which is the hepatic component of the Metabolic Syndrome. NAFLD can worsen to nonalcoholic steatohepatitis, and some experts have wondered if liver exposure to bacteria from the gut could promote this progression.

Researchers, led by Antonio Grieco of Rome , investigated gut permeability in patients with NAFLD and compared the results to patients with untreated celiac disease, who are known to be prone to this condition, and to healthy volunteers.

Their study included 35 patients with biopsy-confirmed NAFLD, 27 with celiac disease and 24 healthy volunteers. The researchers checked the level of small intestinal bacterial overgrowth in each participant using glucose breath testing. They assessed intestinal permeability by looking at urinary excretion of Cr-EDTA. And they examined the integrity of tight junctions within the gut through duodenal biopsies.

"The main findings of this study are that both intestinal permeability and the prevalence of small intestinal bacterial overgrowth are increased in patients with NAFLD and correlate with the severity of steatosis," the authors report. "Disruption of tight junction integrity may explain the increased permeability in these patients."

The authors hypothesize that small intestinal bacterial overgrowth and/or the associated increase in gut permeability may cause steatosis. This idea is supported by studies on mice, and by reports that probiotics can improve steatosis that is the result of a high fat diet.

Importantly, there was no association between either small intestinal bacterial overgrowth or intestinal permeability and steatohepatitis or fibrosis, which argues against a primary role for gut bacteria in the progression of NAFLD to more severe liver disease.

"In conclusion," the authors write, "we have demonstrated that NAFLD is associated with increased intestinal permeability and small intestinal bacterial overgrowth and that these factors are associated with the severity of hepatic steatosis." Further studies are needed to determine the exact causal relationship, and could lead to new therapies for NAFLD that address the microbiome of the gut.

An accompanying editorial by Elisabetta Bugianesi and Ester Vanni of the University of Turin applauds the new findings. "The authors were able to demonstrate both the presence of small intestinal bacterial overgrowth and of increased intestinal permeability in patients with NAFLD, providing the first demonstration of gut leakiness in NAFLD," they write.

"The study by Luca Miele and colleagues raises the possibility that gut microbiota and intestine permeability are important mediators of diet-induced metabolic disturbances in NAFLD," they conclude.

Lifestyle-focused therapy would be best for patients with NAFLD, Bugianesi and Vanni suggest, but manipulating gut flora by antibiotics, prebiotics, and probiotics could help counteract the effect of unbalanced diets on metabolic diseases.


'/>"/>

Contact: Sean Wagner
medicalnews@bos.blackwellpublishing.com
781-388-8550
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Scientists Map Intestinal Bugs Genome
2. Anti-depressant drugs can double risk of gastrointestinal bleeding
3. Endoscopic resection is a safe and effective treatment for gastrointestinal smooth muscle tumors
4. Supratek Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SP1049C for the treatment of metastatic adenocarcinoma of the upper gastrointestinal tract
5. Antegrade bowel intussusception can cause recurrent, chronic postoperative intestinal obstruction
6. The 2008 Gastrointestinal Cancers Symposium
7. Which segments of the gastrointestinal tract does Salmonella enteritidis penetrate?
8. Type 2 diabetes may be caused by intestinal dysfunction
9. Schiff(R) Introduces New Supplement Products for Intestinal Health and Beauty Maintenance
10. ASGE issues updated guidelines on antibiotic prophylaxis for gastrointestinal endoscopy
11. ASGE issues updated infection control guidelines for gastrointestinal endoscopy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... Houston, TX (PRWEB) , ... August 16, 2017 , ... ... named as a Castle Connolly 2017 Top Doctor. The annual list identifies the nation’s ... row that Dr. Vitenas has made it to the top of Castle Connolly’s coveted ...
(Date:8/16/2017)... ... August 16, 2017 , ... SGNA Standards of Infection ... reprocessing cycle, both between patient procedures and before storage, is a requisite practice ... important to the prevention of disease transmission and nosocomial infection as cleaning and ...
(Date:8/16/2017)... ... August 16, 2017 , ... Richard Strawn’s new book ... the time of a cancer diagnosis, surgery and recovery, the Psalms provided encouragement ... many ways God shows love to those who are sick., Surgical Psalms contains ...
(Date:8/16/2017)... NJ (PRWEB) , ... August 16, 2017 , ... ... is offering an opportunity for men and women to train as hospice ... families dealing with life-limiting illness. For over 30 years, the agency has trained ...
(Date:8/16/2017)... ... 16, 2017 , ... Rollon Skin Care Ltd., ... recently announced the launch of two new skincare products, Prache Antiaging Cream and ... expensive plastic surgery or in-patient cosmetic dermatological procedures. , “Prache Antiaging Cream and ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... Second-quarter 2017 revenues of $876 million and ... operations Second-quarter 2017 Branded ... Second-quarter 2017 Sterile Injectables ... Second-quarter 2017 adjusted diluted earnings per ... $0.93 Second-quarter 2017 reported ...
(Date:8/7/2017)... Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent specialty pharmacy, ...  All comparisons, unless otherwise noted, are to the quarter ended ... Second Quarter 2017 Highlights include: Revenue ... 3.5% Total prescriptions dispensed of 220,000, compared ... 7.6% Gross profit per prescription dispensed ...
(Date:8/3/2017)... Aug. 3, 2017  Opioid addiction and other drugs ... healthcare costs and threatening outcomes, were problems taken on ... IVD industry that support them, met this week. This ... said that drugs of abuse, procalcitonin and acute kidney ... the organization,s 69th meeting in San Diego, ...
Breaking Medicine Technology: